Claudio Manubens, MD
Cardiovascular Disease · Davenport, FLNPI 1992700363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,771 of the $13,110 with a category attached, or 89.8%. 40 manufacturers reported payments, led by Biotronik Inc. at 25.0% of the total. Reporting peaked in 2019 at $3,400 and has fallen 51.0% since, to $1,665 in 2025.
Across 382 payments — averaging $34.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Medtronic$995
- Abbott$971
- Amgen$939
- Johnson & Johnson$754
- Bard Peripheral Vascular, Inc.$608
- plus $6K from 34 others
Across 2 payments — averaging $4250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
What the payments were for
- Travel & lodging$1,0998%
- Food & beverage$11,77190%
- Education$2412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 25 | $3,271 |
| Medtronic(2 entities) | 22 | $995 |
| Abbott | 13 | $971 |
| Amgen | 54 | $939 |
| Johnson & Johnson | 44 | $754 |
| Bard Peripheral Vascular, Inc. | 12 | $608 |
| Novartis | 35 | $573 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $463 |
| E.r. Squibb & Sons, L.L.C. | 15 | $455 |
| Impulse Dynamics (USA) Inc. | 9 | $439 |
| Cvrx, Inc. | 6 | $386 |
| Actelion Pharmaceuticals US, Inc. | 10 | $357 |
| Bayer | 19 | $343 |
| AstraZeneca | 11 | $277 |
| Pfizer | 12 | $241 |
| Esperion Therapeutics, Inc. | 11 | $240 |
| Merck | 13 | $227 |
| Cook Medical LLC | 2 | $210 |
| Edwards Lifesciences | 6 | $145 |
| Smith+Nephew | 2 | $127 |
| Penumbra, Inc. | 1 | $120 |
| Insulet Corporation | 1 | $102 |
| W. L. Gore & Associates, Inc. | 3 | $95 |
| Boehringer Ingelheim | 5 | $86 |
| Astellas Pharma US Inc | 2 | $81 |
| Amarin Pharma, Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Heartflow, Inc. | 2 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| United Therapeutics Corporation | 2 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Atricure, Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $25 |
| Cordis US CORP. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$719
- OPTIMIZER$487
- Repatha$365
- Barostim Neo System$316
- Acticor 7 VR-T DX$288
- Solia$281
- Edora$281
- Rivacor$281
- Acticor$281
- Micra$259
- XARELTO$217
- AMPLATZER AMULET$169
- VENOVO$159
- MitraClip$150
- Edora 8 DR-T$147
- Zero Gravity$147
- AVEIR$146
- Confirm Rx$141
- CAMZYOS$125
- Rotarex$125
How this compares
$13,110 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,301 | $763,528 |
| AdempasRiociguat | 19 | $329,293 |
| XareltoRivaroxaban | 312 | $233,385 |
| Repatha SureclickEvolocumab | 159 | $129,995 |
| JardianceEmpagliflozin | 232 | $122,234 |
| EntrestoSacubitril/Valsartan | 171 | $110,014 |
| TrulicityDulaglutide | 92 | $96,757 |
| TivicayDolutegravir Sodium | 29 | $66,712 |
| JanuviaSitagliptin Phosphate | 133 | $59,248 |
| OzempicSemaglutide | 42 | $42,693 |
| Potassium Chloride | 1,074 | $39,350 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $38,314 |
| MyrbetriqMirabegron | 80 | $36,851 |
| Atorvastatin Calcium | 2,274 | $30,810 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $28,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $241 | $763,5281,301 claims |
| BayerAdempas | $343 | $329,29319 claims |
| Johnson & JohnsonXarelto | $754 | $233,385312 claims |
| Boehringer IngelheimJardiance, Tradjenta | $86 | $141,139282 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $21 | $115,474114 claims |
| NovartisEntresto | $573 | $110,014171 claims |
| MerckJanuvia | $227 | $59,248133 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $36,85180 claims |
| Smith+NephewSantyl | $127 | $27,73927 claims |
| AstraZenecaBreztri Aerosphere | $277 | $15,22723 claims |
| Eisai Inc.Fycompa | $16 | $14,26417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Davenport
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.